B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage

Michele Dal-Bo, Ilaria Del Giudice, Riccardo Bomben, Daniela Capello, Francesco Bertoni, Francesco Forconi, Luca Laurenti, Davide Rossi, Antonella Zucchetto, Gabriele Pozzato, Roberto Marasca, Dimitar G. Efremov, Anna Guarini, Giovanni Del Poeta, Robin Foà, Gianluca Gaidano, Valter Gattei

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement.

Original languageEnglish
Pages (from-to)3-14
Number of pages12
JournalBritish Journal of Haematology
Volume153
Issue number1
DOIs
Publication statusPublished - Apr 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Immunoglobulin Heavy Chain Genes
Genes
Superantigens
Antigens

Keywords

  • B cell receptor
  • Chronic lymphocytic leukaemia
  • IGHV3 subgroup
  • Immunoglobulin
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia : The growing saga of the IGHV3 subgroup gene usage. / Dal-Bo, Michele; Del Giudice, Ilaria; Bomben, Riccardo; Capello, Daniela; Bertoni, Francesco; Forconi, Francesco; Laurenti, Luca; Rossi, Davide; Zucchetto, Antonella; Pozzato, Gabriele; Marasca, Roberto; Efremov, Dimitar G.; Guarini, Anna; Del Poeta, Giovanni; Foà, Robin; Gaidano, Gianluca; Gattei, Valter.

In: British Journal of Haematology, Vol. 153, No. 1, 04.2011, p. 3-14.

Research output: Contribution to journalArticle

Dal-Bo, M, Del Giudice, I, Bomben, R, Capello, D, Bertoni, F, Forconi, F, Laurenti, L, Rossi, D, Zucchetto, A, Pozzato, G, Marasca, R, Efremov, DG, Guarini, A, Del Poeta, G, Foà, R, Gaidano, G & Gattei, V 2011, 'B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage', British Journal of Haematology, vol. 153, no. 1, pp. 3-14. https://doi.org/10.1111/j.1365-2141.2010.08440.x
Dal-Bo, Michele ; Del Giudice, Ilaria ; Bomben, Riccardo ; Capello, Daniela ; Bertoni, Francesco ; Forconi, Francesco ; Laurenti, Luca ; Rossi, Davide ; Zucchetto, Antonella ; Pozzato, Gabriele ; Marasca, Roberto ; Efremov, Dimitar G. ; Guarini, Anna ; Del Poeta, Giovanni ; Foà, Robin ; Gaidano, Gianluca ; Gattei, Valter. / B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia : The growing saga of the IGHV3 subgroup gene usage. In: British Journal of Haematology. 2011 ; Vol. 153, No. 1. pp. 3-14.
@article{6164eba4ba2e48b59bdcf48c4a539fc9,
title = "B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage",
abstract = "The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement.",
keywords = "B cell receptor, Chronic lymphocytic leukaemia, IGHV3 subgroup, Immunoglobulin, Prognosis",
author = "Michele Dal-Bo and {Del Giudice}, Ilaria and Riccardo Bomben and Daniela Capello and Francesco Bertoni and Francesco Forconi and Luca Laurenti and Davide Rossi and Antonella Zucchetto and Gabriele Pozzato and Roberto Marasca and Efremov, {Dimitar G.} and Anna Guarini and {Del Poeta}, Giovanni and Robin Fo{\`a} and Gianluca Gaidano and Valter Gattei",
year = "2011",
month = "4",
doi = "10.1111/j.1365-2141.2010.08440.x",
language = "English",
volume = "153",
pages = "3--14",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia

T2 - The growing saga of the IGHV3 subgroup gene usage

AU - Dal-Bo, Michele

AU - Del Giudice, Ilaria

AU - Bomben, Riccardo

AU - Capello, Daniela

AU - Bertoni, Francesco

AU - Forconi, Francesco

AU - Laurenti, Luca

AU - Rossi, Davide

AU - Zucchetto, Antonella

AU - Pozzato, Gabriele

AU - Marasca, Roberto

AU - Efremov, Dimitar G.

AU - Guarini, Anna

AU - Del Poeta, Giovanni

AU - Foà, Robin

AU - Gaidano, Gianluca

AU - Gattei, Valter

PY - 2011/4

Y1 - 2011/4

N2 - The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement.

AB - The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement.

KW - B cell receptor

KW - Chronic lymphocytic leukaemia

KW - IGHV3 subgroup

KW - Immunoglobulin

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79952593462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952593462&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08440.x

DO - 10.1111/j.1365-2141.2010.08440.x

M3 - Article

C2 - 21303354

AN - SCOPUS:79952593462

VL - 153

SP - 3

EP - 14

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -